Pulmonary Arterial Hypertension in Patients Treated by Dasatinib

Study Questions:

Does use of the tyrosine kinase inhibitor dasatinib in the setting of chronic myelogenous leukemia (CML) result in precapillary pulmonary hypertension (PAH)?